Humana Inc. (NYSE:HUM) Shares Purchased by Quent Capital LLC

Quent Capital LLC lifted its holdings in Humana Inc. (NYSE:HUM) by 47.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 300 shares of the insurance provider’s stock after acquiring an additional 96 shares during the quarter. Quent Capital LLC’s holdings in Humana were worth $112,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HUM. Trust Point Inc. acquired a new stake in shares of Humana in the fourth quarter worth $505,000. International Assets Investment Management LLC boosted its holdings in Humana by 32,648.4% during the fourth quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock worth $61,619,000 after buying an additional 134,185 shares in the last quarter. Prime Capital Investment Advisors LLC boosted its holdings in Humana by 36.6% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 1,130 shares of the insurance provider’s stock worth $517,000 after buying an additional 303 shares in the last quarter. Stratos Wealth Partners LTD. boosted its holdings in Humana by 21.3% during the fourth quarter. Stratos Wealth Partners LTD. now owns 1,570 shares of the insurance provider’s stock worth $719,000 after buying an additional 276 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its holdings in Humana by 10.2% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 241,282 shares of the insurance provider’s stock worth $110,722,000 after buying an additional 22,300 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HUM. Royal Bank of Canada lowered their price target on shares of Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Wells Fargo & Company lowered their price target on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Oppenheimer increased their price objective on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Bank of America increased their price objective on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a report on Monday, May 20th. Finally, Jefferies Financial Group decreased their price objective on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a report on Monday, April 22nd. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and an average price target of $403.55.

Humana Trading Down 0.3 %

Humana stock traded down $0.97 during midday trading on Tuesday, hitting $355.32. 930,729 shares of the stock were exchanged, compared to its average volume of 1,739,943. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The stock has a market capitalization of $42.78 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 2.09 and a beta of 0.51. The stock’s 50-day simple moving average is $368.04 and its 200 day simple moving average is $347.41. The company has a current ratio of 1.66, a quick ratio of 1.67 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period last year, the business earned $8.94 earnings per share. Humana’s revenue was up 10.4% compared to the same quarter last year. On average, equities analysts anticipate that Humana Inc. will post 16.14 EPS for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.